Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
metabolic drugs
Biotech
Aligos MASH prospect slashes liver fat in phase 2
Aligos is heralding a mid-stage MASH win after its candidate slashed liver fat at three different doses. Still, investors weren't impressed.
Gabrielle Masson
Sep 19, 2024 1:00pm
Skye ends eye disease R&D after glaucoma drug's phase 2 fail
Jun 10, 2024 8:51am
Chinese biotech's MASH drug reduces liver fat in phase 2 trial
Mar 18, 2024 11:07am
Lindus hops on GLP-1 hype with CRO service for metabolic disease
Mar 6, 2024 12:45pm
Novo Nordisk unveils new US hub as R&D investments soar
Feb 29, 2024 5:00am
Roche signs onto Alnylam's midstage hypertension med for $310M
Jul 24, 2023 11:00am
